Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

StockNews.AI • 2 days

BullishShort TermCorporate DevelopmentsGuggenheim Securities Cantor Fitzgerald

High Materiality9/10

Information

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), ...

AI Summary

Phathom Pharmaceuticals is initiating a public stock offering to support its working capital and R&D efforts. Managed by Guggenheim and Cantor, the offering includes a 30-day option for underwriters to purchase additional shares. The effectiveness of these plans hinges on market conditions and timing.

Trading Thesis

Investing in PHAT could be advantageous if the capital raise positively impacts growth initiatives.

Market-Moving

Phathom's public offering aims to bolster financial operations.
Investors are poised to assess the market's reaction to the offering.
Successful capital raise may boost PHAT's business development plans.

Key Facts

Phathom is focused on gastrointestinal disease treatments.
They market VOQUEZNA for GERD and H. pylori infections.
The offering involves pre-funded warrants for certain investors.
Effective upon filing, the registration statement seeks to raise capital.

Companies Mentioned

Guggenheim Securities (N/A): Joint bookrunning manager for Phathom's offering.
Cantor Fitzgerald (N/A): Partnering with Guggenheim for capital raising efforts.

Corporate Developments

The public offering indicates Phathom's proactive approach to enhancing its financial stability and funding growth areas, particularly in R&D. Such movements are common in biopharma to finance ongoing projects and expedite product development.

FAQ

Why Bullish?

Raising capital through an offering is generally positive for funding growth initiatives. Historical examples show that successful offers can lead to better market positions post-funding.

How important is it?

The significance of the offering directly relates to PHAT's ability to sustain and enhance its gastrointestinal treatments through forthcoming R&D efforts, making it highly relevant to investors.

Why Short Term?

The immediate effects of the offering will likely be seen in share price fluctuations as market sentiment reacts quickly to capital raising news. Examples include short-term price spikes following similar offerings in the biotech sector.

Related Companies

Guggenheim Securities Cantor Fitzgerald

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

FLORHAM PARK, N.J., January 07, 2026 (GLOBE NEWSWIRE) – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company specializing in treatments for gastrointestinal diseases, has revealed plans to conduct an underwritten public offering of its common stock. The offering may also include pre-funded warrants for eligible investors who prefer this option, subject to market conditions.

Details of the Proposed Offering

Phathom Pharmaceuticals is proposing to sell shares of its common stock and may grant underwriters a 30-day option to purchase up to an additional 15% of the total number of securities offered. However, the company cautions that there is no assurance regarding the completion, size, or terms of this offering.

The net proceeds from this public offering are intended for general corporate purposes, including:

Working capital needs
Commercialization efforts
Research and development expenses

Underwriters Involved

Guggenheim Securities and Cantor Fitzgerald are acting as joint bookrunning managers for this offering. The securities are being offered pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on January 7, 2026, which became effective automatically upon filing.

Accessing the Prospectus

Investors interested in this public offering can expect a written prospectus, including a prospectus supplement, to be part of the registration statement. Once available, copies can be obtained from:

Guggenheim Securities, LLC, Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017. Phone: (212) 518-9544. Email: GSEquityProspectusDelivery@guggenheimpartners.com.
Cantor Fitzgerald & Co., Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022. Email: prospectus@cantor.com.

Additionally, electronic copies will be accessible on the SEC’s website at http://www.sec.gov.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is dedicated to developing innovative treatments for gastrointestinal diseases. The company has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Canada, and Europe. In the United States, Phathom markets vonoprazan under the brand name VOQUEZNA®.

VOQUEZNA® is indicated for:

Relief of heartburn associated with Non-Erosive GERD
Healing and maintenance of healing of Erosive GERD
Treatment of H. pylori infection as part of VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®

Forward-Looking Statements

Phathom encourages cautious interpretation of the statements contained in this release, particularly those that pertain to anticipated developments and business operations. Actual results may differ from projections due to various market conditions and closing conditions related to the offering. Investors should refer to the company’s prior filings with the SEC for detailed risk factors.

Contact Information

For media inquiries, please contact:

Nick Benedetto, Media Relations: 1-877-742-8466, media@phathompharma.com

For investor-related questions, please contact:

Eric Sciorilli, Investor Relations: 1-877-742-8466, ir@phathompharma.com